New AJT Publication: AlloSure is the Only cfDNA Test Proven to Differentiate Ambiguous Rejections
Currently, there is a lack of consensus on the impact of a TCMR 1A or borderline rejection diagnosis, and significant issues in interobserver pathology assessment. All patients in the study were diagnosed with TCMR 1A or borderline rejection. Those patients with AlloSure scores greater than 0.5% went on to have declining eGFR, a signal of deteriorating graft function and lower prediction of survival. However, those patients with AlloSure scores below 0.5% had almost no change in eGFR. The AJT publication illustrates how AlloSure can risk stratify the population with ambiguous rejections and enable personalized care for transplant patients.
“These data on bifurcation of patients that we were grouping as TCMR can have a significant impact on how we treat patients. The AJT publication highlights the value of large registry datasets like KOAR and OKRA where we can capture these key insights that impact our clinical practices,” said
“CareDx continues to focus on new science and innovation in transplantation that impacts how patients are cared for. Deep down, we believe that some patients are over immunosuppressed, and the patients who are treated for ambiguous rejections are a perfect case example of where we see the immediate impact of surveillance with AlloSure,” said
For more information, please visit: www.CareDx.com.
Chief Marketing Officer
Source: CareDx, Inc.